Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Study examines limited-field radiation for early breast cancer


Data from a five-year study suggests that limited-field radiation therapy (radiation directed at the tumor site) may be as effective as whole-breast radiation therapy in preventing breast cancer recurrence in women treated with breast-conserving surgery. The study appears in the August 20 issue of the Journal of the National Cancer Institute.

Whole-breast radiation therapy is part of standard treatment for women with early-stage breast cancer who have undergone breast-conserving surgery. However, it has never been clear how much tissue surrounding the tumor bed needs to be irradiated, and whole-breast radiation therapy has been associated with both acute and chronic toxicity. Researchers are now looking at whether limited-field radiation therapy could be a better option for patients at low risk for recurrence.

Frank A. Vicini, M.D., of the William Beaumont Hospital in Royal Oak, Mich., and his colleagues compared rates of local recurrence between 199 women treated with limited-field radiation therapy and 199 matched control women treated with whole-breast radiation therapy. All of the women had early-stage breast cancer and were treated with breast-conserving surgery; women were matched by age, tumor size, lymph-node status, margins of excision, estrogen receptor status, and use of adjuvant tamoxifen therapy.

After five years of follow-up, there was no difference in the median time to recurrence and rate of local recurrence between women in the two treatment groups, nor was there any difference in the rates of distant metastases, disease-free survival, overall survival, or cause-specific survival.

"These results suggest that, in appropriately selected early-stage breast cancer patients, limited-field radiation therapy may be adequate in controlling residual disease after breast-conserving therapy," the researchers write, adding that these results raise the question of whether whole-breast radiation therapy is necessary in certain low-risk patients.

The authors point out that several phase III trials are under way in Europe to compare standard whole-breast radiation therapy with limited-field radiation therapy using different techniques and radiation schedules. "Data from these studies will potentially provide invaluable information on the requisite volume of breast tissue requiring treatment and the range of patients appropriately managed with limited-field radiation therapy," they write.

In an accompanying editorial, C. Norman Coleman, M.D., and his colleagues at the National Cancer Institute caution that extended follow-up will be needed to determine any late recurrences or late toxicity, which may take 10 or more years to manifest.

"Only by successfully completing a clinical trial on the equivalency of partial-breast irradiation with whole-breast irradiation can we provide definitive answers for those physicians and patients yet to face the decision about treatment options for early-stage breast cancer," they conclude.

Contact: Colette Stimmell, William Beaumont Hospital, 248-551-0740; fax: 248-551-8175,

Editorial: NCI Press Office, 301-496-6641; fax: 301-496-0846,

Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 2003;95:1205–11.

Editorial: Coleman CN, Wallner PE, Abrams JS. Inflammatory breast issue. J Natl Cancer Inst 2003;95:1182–4.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Linda Wang | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Custom sequences for polymers using visible light

22.03.2018 | Materials Sciences

Scientists develop tiny tooth-mounted sensors that can track what you eat

22.03.2018 | Health and Medicine

Mat baits, hooks and destroys pollutants in water

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>